Ma lignant schwannoma is an agg ressive tumor that ca rries a poor p rognosis despite wid e excision, chemothe rapy, and radio therapy. Ma ligna nt scliwannoma of the pa raphary ngeal space is an uncom mon finding; to our know ledge, only fo ur cases have been described in the literature during the pas t 30 years, and only one ofthem invo lved a patient who had clinical ev idence of neurofibromatosis type 1. In this article , we describe a new cas e of malignant schwannoma of the pa rapharyngeal space in a patient who had clinical evidence ofneurofibromatosis type 1. Following resection of the tum or and a total parotidectomy, the diagnosis was made on the basis of histology and immun ohistoch emistry. The patient und erwent postoperative chemothe rapy with carboplatin and UP16. How ever, 5 months f ollowin g sur gery, the tumor recurred and metastasized. The patient was then placed on a different polychemotherap eutic regim en, which was made up of3 g/m' ofifosfamide, 1.5 mg/m' of vincristine, and 1.5 mg/m ' of doxorubicin (I VA 2 protoco l). The I VN regim en slowed tum or growth, but 13 month s after the initiati on of therapy, the pat ient died of neoplastic cachexia. A lthough chemotherapy is generally ineffecti ve in most cases of malignant schwanno ma, we did expe rience som e positi ve results with the IVA 2 protocol. Therefore, we recommend that this combination be cons idered as a first-line adj uvant therapy following surge ry or as a first-line therapy for pa tients with inoperable tumors.
Introduction
Neurofibromatosis type I (von Reckl inghausen' s disease) is a hereditary illness. Clinic al symptoms includ e cafe au lait spots, sess ile or pedun culated derm al tumors, and tumors of the peripheral nerves. Neurofibrom atosis is known to be complicated by malignant tumors, most of which are of soft-tissue origin. The reported incidence of transform ati on of neurofibromas int o mal ign ant schwannomas ranges from 3 to 30%; only a small percentage of these transformation s occur in the head and neck area. [1] [2] [3] Malign ant schwannoma is a highly aggress ive tumor that carries a poor prognosis.' It requires a precise, early diagnosis based on imaging techniques and immunohistochemical studies so that an appropriate line of treatment can be determined. For low-grade tumors, the recommended treatment is surgery. For high-grade tumors, aggre ssive surgical resection with wide tumor-free margins supplemented by postoperative irradiation and/or chemotherapy is recommended.':'?Overall, chemotherapy alone is generally con sidered to have little effect on survival,11-14 but its effic acy as an adj uvant treatment has yet to be clarified :
In this article, we describe the clinica l histor y of a young man affected by neurofibromatosis type I whose ' neuro fibroma of the parapharyngeal space transformed into a malignant schwa nnoma. Based on our experie nce with this case , we can sugge st a new therapeutic regimen for malignant schwannoma.
Case report
In November 1996, a 25-year-old man with diffu se neurofibromatosis type 1 and multipl e cafe au lait spots was admitted to the Dep artment of Otolaryn golo gy for evaluation of a painful tumo r mass in the left parotid gland that had caused earache and dysphagia . On exa mination, the tumor in the parotid area measured approxi mately 4 x 3 x 1.5 em.
Magnetic resonance imagin g (MRI) showed that the mass was located in the parapharyngeal space and extended into the deep lobe of the parotid gland (figure I). A smaller mass was see n insid e the left parotid. Wid e resection of the tumor combined with a total left parotidectomy was carried out. Th e facial nerve was spared. Frozen-section examination of the tumor specimen confirm ed the suspicion that it repr esented a neurofibroma that had transformed into a malignant schwa nnoma. Histologically, the tumor was made up of compact band s of polymorphous and polymetri c cells with lept ochromatic nucl ei (fig ure 2 ). Immunohistochemical studies showed positi ve staining of tumor ce lls for vimentin and foca lly for S-I 00 protein.
Rad io-and chemotherapy were not carried out becau se the histologic exa mination appeared to confirm that the tumor had been co mpletely removed by wide-margin rese ction. Howe ver,S months later, in April 1997, the patient returned to us with a rec urrence in the left parotid area . Th e mass had grow n to 13 em in diameter in only a few days. Enlarged exeresis of the recurrent lesion was performed, including removal of the asce nding ramu s of the mandible and the skin of the parotid area. The skin defe ct was recon structed with a musculocutaneous flap taken from the pectoralis maj or and with a gauntlet (pedicle) flap taken from the temporal is. In May 1997, chem otherapy with 500 mg/m? of carboplatin and 150 mg/rn? of UPI 6 was administered. However , a few weeks later, the patient developed a new recurrence while undergoing che motherapy, and the tumor rapidl y grew to 20 em in diam eter. Computed tom ography (CT) revealed that the tum or had invaded the left pterygopalatin e fossa, the infratemporal fossa, and the skull base with infiltration of the petrous portion ofthe left temp oral bone and the left cave rno us sinus ( figure 3) .
Becau se of the size of the tumor and its continuou s surface exudation, the patient did not wish to appear in publi c. The refore, surgical debulking was carried out to impro ve the patient' s rem ainin g qu ality of life . In July 1997 , the patient was started on 3 g/m? of ifosfamide , 1.5 mg/m-of vincristine, and 1.5 mg/m ? of doxorubicin (IVN) . Initially, there was evidence of a partial response to chemotherapy , and for 13 months, this anti blastic regimen appeared to slow the growth of the tumor. Howeve r, in August 1998, the patient died of neoplastic cachexia.
Discussion
Malignant sch wannoma-also known as neurogenic sarcoma, neurofib rosarc oma, malignant neurofib roma, and recentl y ren amed malignan t periphera l nerve sheath tumor-is a rare form of cancer that acco unts for 5% of all soft-tiss ue tumors and affects 0.00 I% of the populati on .v" In 25 to 70 % of cases, malignant schwa nnoma is ass ociated with neuro fibrom atosis.3.15-17 Th e percent age appears to be higher in pati ents who have a family history of neuro fibrom atosis.
Malignant schwannoma usually arises in the extr emities, but it can affect any part of the bod y. In fact, cases of malignant schwannoma have been repo rted in the submandibular, zygomatic, and buc cal area s, in the maxillary sinus, in the nasal fos sa, in the esoph agu s, in the thoracic Surgery is uni ver sally recognized as the best fo rm of treatm ent .v-? Surgery should be carri ed out in all cases in wh ich ample local exeresis is po ssibl e. It may be combined with a course of postop radiotherapy .2,4.6.8.10.24.28 Radioth er ap y is con sid ered a useful palliative mod alit y in cases in whi ch the surro unding struc tures hav e been invaded and the tumor cannot be enucleated.P Radiothe rapy is admi nistered to redu ce the po ssibility of loc al recurrence and to treat cases of isol ated recurren ce and tum or s that cannot be exc ised. However, it is well known that mal ignant schwa nnoma is usually resist ant to both radio-and che mo therapy, although chemotherapy may pla y a role in the tre atment of surgica l failures .4.6.8. 24.25.29.3o In such cas es, different chemoth erapeutic age nts' have been utilized sing ly or in combination. Sordillo et al" suggested that chemo therapy might be effec tive in cases of associ ated neurofibr om ato sis typ e 2, but the meager amount of data in the literatu re is frankly di she artenin g." :" Some success has been rep orted , but only in isolated case rep ort s as oppo sed to clinic al studies . For exampl e, Ohnishi et al described a case of mali gnant schwannoma of the mandibular nerve th at was treated with surgery and chemotherap y; the patient had no evidenc e of dise ase at 5 year s of follow-up." Bruckner et al 864 reported the complete regression of an inoperabl e mal ignant schwannoma of the posterior neck after co mbine dmodality treatment with radi o-and chem oth erap y (vinblastin e plu s do xorub icinj." Athow and Kirkham observed a partial resp on se to chemot herapy in the treatm ent of a malignant schwannoma of the parotid gland." Most recentl y, Zanon et al suggested that despite the ge nera l ineffectiveness of che mo therapy, the most active dru gs in the contro l of tumor growth in malignant schwannoma are decarb azin e, doxorubicin , and ifosfamide." In our patient , onl y IVN (our seco nd line of therap y) appeared to control the grow th of the tum or. In fac t, we observed clinicall y that the siz e of the tum or remained unchanged for a long period.
We acknowledge that chemo therapy has littl e value in most cases, but in our ex perience , the IVA 2 chemo therapeutic protocol yielded a goo d short-term result in controlling tum or growth. Th erefore, we emphasize the necessity of continuing research to find an effec tive adj uvant therapy, and we suggest that IVN be conside red as a firs t-line ch oice as an adjuvan t treatm ent foll owin g surgery or a fir st-line treatment for patient s with an inoperable malig nan t schwannoma. mal injury, altere d blood flow, and hypercoagul able blood).' Hyperhomocysteinemia can cause thromb osis either directly or indirect ly. For exa mple, Lentz wro te that homocysteine can inhibit endothelial producti on of nitric oxide, which has antiplatelet acti vity and is known to prevent vasoconstriction." Lentz also reported that oxidation of homocysteine can genera te reactive oxygen species, such as hydrogen peroxide, superox ide anion, and hydroxyl anio n. These reactive oxygen species may impair the endothelium-dependent acti vation of protein C, thus predisposing a patient to thromb osis. Hyperhomocys teinem ia may also stimulate a proliferation of vascular smoo th muscle cells.
The patient described here was treated with folic acid and a daily multi vitamin that contained B supplements. Alth ough it is not known whether thrombosis can be prevented with these supplements, she remained clot-free 15 month s afte r the initiation of therap y.
